These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 32672820)
1. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. Tamirisa N; Lin H; Shen Y; Shaitelman SF; Sri Karuturi M; Giordano SH; Babiera G; Bedrosian I JAMA Oncol; 2020 Oct; 6(10):1548-1554. PubMed ID: 32672820 [TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis. Tamirisa N; Lin H; Shen Y; Shaitelman SF; Karuturi MS; Giordano SH; Babiera GV; Bedrosian I Cancer; 2021 Jul; 127(13):2196-2203. PubMed ID: 33735487 [TBL] [Abstract][Full Text] [Related]
3. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy. Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783 [TBL] [Abstract][Full Text] [Related]
4. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995 [TBL] [Abstract][Full Text] [Related]
5. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer. Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473 [TBL] [Abstract][Full Text] [Related]
6. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores. Chen J; Wu X; Christos PJ; Formenti S; Nagar H Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221 [TBL] [Abstract][Full Text] [Related]
7. Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. Tamirisa N; Thomas SM; Fayanju OM; Greenup RA; Rosenberger LH; Hyslop T; Hwang ES; Plichta JK Ann Surg Oncol; 2018 Oct; 25(10):2890-2898. PubMed ID: 29968029 [TBL] [Abstract][Full Text] [Related]
8. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632 [TBL] [Abstract][Full Text] [Related]
9. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men. Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030 [TBL] [Abstract][Full Text] [Related]
10. A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer. Ozer M; Goksu SY; Sanford NN; Porembka M; Khurshid H; Ahn C; Maxwell MC; Beg MS; Kazmi SM JAMA Netw Open; 2022 Feb; 5(2):e2146912. PubMed ID: 35171262 [TBL] [Abstract][Full Text] [Related]
11. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424 [TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology). Inal A; Akman T; Yaman S; Demir Ozturk S; Geredeli C; Bilici M; Inanc M; Harputoglu H; Demirci U; Balakan O; Yesil Cinkir H; Alici S; Uysal Sonmez O; Goksel G; Gokoz Dogu G; Umit Unal O; Tamozlu T; Buyukberber S; Melih Boruban C; Isikdogan A J BUON; 2013; 18(1):64-9. PubMed ID: 23613390 [TBL] [Abstract][Full Text] [Related]
13. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Leone JP; Cole BF; Regan MM; Thürlimann B; Coates AS; Rabaglio M; Giobbie-Hurder A; Gelber RD; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Goldhirsch A; Di Leo A; Colleoni M; Vaz-Luis I; Lin NU Cancer; 2021 Mar; 127(5):700-708. PubMed ID: 33290610 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial. Xiang HY; Liu YH; Zhang H; Zhang S; Xin L; Xu L; Ye JM; Li T; Duan XN; Liu Q Chin Med J (Engl); 2019 Dec; 132(24):2914-2919. PubMed ID: 31809316 [TBL] [Abstract][Full Text] [Related]
15. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients. Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497 [TBL] [Abstract][Full Text] [Related]
17. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Buszek SM; Lin HY; Bedrosian I; Tamirisa N; Babiera GV; Shen Y; Shaitelman SF Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):795-802. PubMed ID: 31377160 [TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiation therapy alone is associated with improved overall survival compared to hormonal therapy alone in older women with estrogen receptor positive early stage breast cancer. Jhawar SR; Alpert N; Taioli E; Sayan M; Bazan J; Park KU; Stover D; Cherian M; White J; Haffty B; Ohri N Cancer Med; 2020 Nov; 9(22):8345-8354. PubMed ID: 32942344 [TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246 [TBL] [Abstract][Full Text] [Related]